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Both recombinant blood coagulation factor XIII u-chain and factor XIII isolated from human placenta have been crystallized using a novel robotic 
system for the automatic screening of crystallization conditions. The monoclinic and orthorhombic rystals obtained are suitable for X-ray analysis. 
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1. INTRODUCTION 
Factor XIIIa (FXIIIa; fibrinoligase activated fibrin- 
stabilizing factor, EC 2.3.2.13 [protein-glutamine: 
amine y-glutamyltransferase]) is the last enzyme ac- 
tivated in the blood coagulation cascade [1,2]. Being a 
transglutaminase, it catalyzes the formation of inter- 
molecular y-glutamyl-f-lysyl isopeptide bonds between 
fibrin molecules [3] and between fibrin and cyz-plasmin 
inhibitor [4], thereby stabilizing the blood clot and con- 
fering resistance to proteolytic degradation by plasmin. 
Other substrates of FXIIIa include fibronectin and col- 
lagen [5,6], explaining why the enzyme also plays an 
important role in wound healing [7]. 
In blood plasma, the enzyme exists as a tetrameric 
zymogen designated factor XIII (FXIII), composed of 
two 83-kDa u-subunits and two 85kDa b-subunits 
(a&) [l-3]. Activation under physiological conditions 
occurs via a series of events involving (2) cleavage by 
thrombin of the bond between Arg-37 and Gly-38 of 
the a-chain(s) and release of the NH2 (terminal 37) 
residue activation peptide [8]; (ii), binding to fibrin [9]; 
(iii), dissociation of the noncatalytic b-chains from the 
tetramer to yield the az-dimer [l]; and (iv), a conforma- 
tional change induced by binding of Ca2+ ions to the a- 
subunits. 
The corresponding zymogens isolated from platelets 
or placenta lack the b subunits and consists of 
az-homodimers. Presumably, their a-chains are iden- 
tical to those of the plasma proenzyme [2,7,10], and the 
steps of the Ca2+-dependent conversion to FXIIIa by 
thrombin cleavage are also the same as described 
above, except for step (iii) [l-3,8, 11-141. 
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The primary structure of the catalytic a subunit has 
been reported recently [ 10, 15, 161, and the human gene 
coding for it has been characterized [17]. Except for its 
relationship to some tissue transglutaminases [17], for 
which FXIII a-chain is a prototype, the amino acid se- 
quence of the enzyme is unique. However, a short seg- 
ment around the putative active site residue Cys-314 
[18] exhibits limited similarity to the active center of 
cysteine proteases uch as cathepsins B and H, papain 
[ 191 and calotropain [20]. 
In order to shed light on the mechanism of this im- 
portant enzyme, we have crystallized both recombinant 
human FXIII a-chain and the zymogen isolated from 
human placenta by a novel technique and initiated the 
elucidation of its three-dimensional structure by X-ray 
crystallography. 
2. MATERIALS AND METHODS 
2.1. Protein purification 
Factor XIII from placenta was isolated and purified as described 
in [13]. For preparation of recombinant FXIII a-subunit (rFXIII), 
cDNA coding for the placental factor [15] was cloned and expressed 
in yeast (S. cerevisiae). Isolation of rFXIII from the crude cell extract 
to more than 95% purity was achieved by salt precipitation, ion- 
exchange and gel filtration chromatography (to be published 
elsewhere). In SDS-PAGE rFXII1 and FXIII isolated from placenta 
showed identical molecular weights. Also, both could be activated by 
thrombin to comparable specific activities. 
2.2. Crystallization procedure 
The technique of isothermal vapour diffusion in its ‘hanging drop’ 
variant [21] was used to screen for crystallization conditons. Handl- 
ing of all solutions during set-up of the experiments was performed 
by a microcomputer-controlled robotic system described in [22] and 
manufactured by ICN Biomedicals, Horsham, PA, USA. Sixteen 
crystallization experiments were performed in a 4 x 4 array on Lin- 
bro depression plates (Flow Laboratories, McLean, VA, USA). Solu- 
tion pH was varied in the columns and precipitant concentration in 
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the rows. Citrate/phosphate or tris(hydroxymethyl)aminomethane 
(Tris) HCl, were used as two-component buffer systems to maintain 
solution pH. The volume of each component necessary to yield a 
given pH was taken from data tables stored previously in the 
microcomputer. Precipitants used were ammonium sulfate, am- 
monium acetate, or polyethyleneglycol4000 (PEG); their appropriate 
dilutions were calculated from the given concentration in stock solu- 
tions. The computed volumes of buffer and precipitant solutions 
were automatically dispensed into individual wells of the crystalliza- 
tion plates. Each well was filled to 1 ml by addition of doubly distilled 
water. After the wells were filled, 4 4 droplets from each well were 
transferred to 22 mm diameter plastic coverslips (Flow Laboratories), 
positioned on a Plexiglas template next to the x,y translation table of 
the system. Finally, a 4 ~1 droplet of protein solution (12 mg/ml) was 
added to each buffer droplet on the coverslips which were then 
manually inverted over the appropriate well and sealed in place by a 
layer of silicon grease. Crystallization dishes were stored at room 
temperature or at 4°C and inspected daily. 
2.3. X-ray data collection 
Diffraction qualities of crystals were inspected and three- 
dimensional data sets collected using a FAST television area detector 
system with a CAD4 four-circle goniostat mounted on a FR 571 
rotating anode X-ray generator, operated at 4.5 kW, with 0.3 mm 
focus (all X-ray equipment from Enraf Nonius, Delft, The 
Netherlands). The radiation used was monochromatized CuK,. Data 
were collected on the detector as a series of discrete electronic images, 
each comprising an oscillation of 0. lo. Data acquisition and evalua- 
tion were carried out under the control of the MADNES software 
[24]. Unit cell constants and Bravais lattice type were determined by 
an autoindexing [25] procedure written by Dr. P. Tucker and con- 
firmed by checking the equivalence of symmetry-related intensities. 
Partial diffraction data sets were also collected at the EMBL 
Outstation at DESY, Hamburg, FRG, using synchrotron radiation of 
wavelength X = 0.965 A at the high intensity beam line X-11 of the 
DORIS storage ring (collaboration with Drs. C. Betzel and K.S. 
Wilson, to be published elsewhere). The detector was a novel imaging 
plate system developed by Dr. J. Hendrix et al. (EMBL). 
3. RESULTS 
Automated screening of crystallization conditions 
for both placenta and recombinant FXIII was initiated 
by experiments in which solution pH and precipitant 
concentration were varied over wide ranges. Using am- 
monium sulfate as a precipitant, thin needle-like 
crystals were obtained in a wide array of conditions. 
Since these needles were not useful for X-ray diffrac- 
tion experiments, no attempt was as yet made to im- 
prove their size by refining the crystallization 
conditions. When 4000 MW polyethylene glycol (PEG) 
was used as the precipitating agent, crystals exhibiting 
three different types of morphology could be 
distinguished already in early screening experiments. At 
pH 6.9, PEG concentrations around 3.5% (w/v) led to 
the formation of needles after l-3 days, whereas skew- 
ed hexagons were observed at pH 6.5 -7.6 and 
5.0 - 8.0 Vo (w/v) PEG. Finally, lower PEG concentra- 
tions (2Vo) yielded crystals of a more irregular, 
prismatic shape at pH 6.3 - 6.5. Crystals exhibiting the 
latter two habits tended to appear simultaneously in the 
same droplet in the intermediate precipitant concentra- 
tion range and were indeed shown by X-ray diffraction 
experiments to have identical unit cells (see below; 
Fig.]. Form I crystals of factor XIII, obtained from 6.5 % (w/v) 
polyethylene glycol 4000. 
subsequently called crystal form I). All crystals were ac- 
companied by a bulk protein precipitate. The observa- 
tions described above were identical for both rFXII1 
and the factor isolated from human placenta. 
In a separate series of experiments which used am- 
monium acetate as a precipitant, we obtained yet 
another crystal form with both placenta and recombi- 
nant FXIII. The shape of these crystals was again 
prismatic but they were crystallographically clearly 
distinct from the form I prisms observed at low PEG 
concentrations. This crystal form will be designated 
form II in the following. It is noteworthy that these 
crystals were accompanied by less amorphous 
precipitate than those grown from PEG. 
The strategy adopted to improve the crystals of both 
forms was that of successive grid searches as described 
by Cox and Weber [22,23]. Smaller ranges of pH and 
precipitant concentration were centred about grid 
points that yielded crystals in the previous experiment. 
Thus, the optimum conditions for growth of the form 
Fig.2. Form II crystals of factors XIII, obtained from 10.5 % (w/v) 
ammonium acetate. 
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I crystals were established as 6.5% (w/v) PEG, pH 7.2, 
room temperature. These crystals reached a maximum 
size of 0.3 x 0.3 x 0.15 mm3 (Fig. 1). Conditions for 
form II crystals were refined to 10.5% (w/v) NHdOAc, 
pH 7.4. These crystals grew to a size of 0.3 x 0.3 x 
0.2 mm” (Fig. 2). 
Nearly complete three-dimensional data sets were 
collected from crystals of both forms using a FAST 
television area detector [24]. The skewed hexagons 
(form I) diffracted to a resolution limit of 2.8 A, which 
could be improved to 2.7 A when synchrotron radiation 
and an imaging plate detector were used (details to be 
published elsewhere). The cell constants were deter- 
mined as a = 101.0(l), b = 72.3(2), c = 133.2(2) A, 
,L? = 106.6(l)’ (SDS from a total of five crystals), and 
the space group was monoclinic, P21. The cell axes 
agreed to within 0.2 A between crystals of recombinant 
and placenta FXIII. Assuming two molecules, i.e. one 
a2 dimer, per asymmetric unit, the packing density of 
these crystals was calculated as V, = 2.79 A3/Da, 
which is well within the range observed for most pro- 
tein crystals [26]. The solvent content of these crystals 
was estimated to be 56%. 
The prismatic crystals of form II exhibited a diffrac- 
tion limit of 3.5 A resolution and were less stable in the 
X-ray beam. A resolution limit of 3 .O A was achievable 
with synchrotron radiation. The space group was or- 
thorhombic, most probably P212121, with cell constants 
a = 95.4(2), b = 101.0(2), c = 181.4(4) A (only deter- 
mined for form II crystals of the recombinant 
material). Assuming one FXIII a2 dimer per asym- 
metric unit, the packing density was calculated as V,,, = 
2.63 A3/Da, again well within the range normally 
observed [26]. The solvent contents of these crystals 
was 53%. 
4. DISCUSSION 
Obtaining sufficiently large single crystals of proteins 
is a prerequisite for the determination of their three- 
dimensional structures by X-ray crystallography. 
Nucleation and growth of protein crystals is influenced 
by a large number of parameters the interplay of which 
is poorly understood, thus making systematic ap- 
proaches difficult and leading to the common notion 
that protein crystallization has remained an art rather 
than become a science [27]. However, in recent years 
physicochemical studies of the processes occurring 
prior to and during crystallization have provided a bet- 
ter understanding of the role of at least some of the 
crystallization parameters [28], and robotic systems 
aiming at more systematic investigations of crystalliza- 
tion conditions have been developed [22]. 
Using the automated procedure described by Cox 
and Weber [22,23], we were able to grow X-ray grade 
crystals of the FXIII a2-dimer. The amount of protein 
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needed to establish optimum growth conditions for two 
different crystal forms was about 20 mg. This figure 
could have been decreased considerably by use of pro- 
tein droplet volumes smaller than 4 pl. Therefore, it 
seems that automatization of protein crystallization 
trials indeed not only results in a substantial increase in 
experimental precision, accuracy and, hence, repro- 
ducibility but also allows to systematically scan much 
larger ranges of crystallization conditions with limited 
amounts of protein material than possible with the 
traditional trial-and-error methods. 
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